PEN (Penumbra) Cyclically Adjusted Revenue per Share: $23.17 (As of Mar. 2026)


PEN Penumbra Inc PEN
89 GF Score
Price $318.49
GF Value $332.07
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Cyclically Adjusted Revenue per Share?

Penumbra PEN -0.03% 89 Cyclically Adjusted Revenue per Share is $23.17 as of Mar. 2026. GuruFocus rates PEN with a GF Score™ of 89/100 and a GF Value™ of $332.07 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Penumbra's adjusted revenue per share for the three months ended in Mar. 2026 was $9.477. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $23.17 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Penumbra's average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-06), Penumbra's current stock price is $318.49. Penumbra's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $23.17. Penumbra's Cyclically Adjusted PS Ratio of today is 13.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Penumbra was 16.30. The lowest was 9.44. And the median was 13.00.


Penumbra  (NYSE:PEN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Penumbra's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=318.49/23.17
=13.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Penumbra was 16.30. The lowest was 9.44. And the median was 13.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Penumbra Cyclically Adjusted Revenue per Share Related Terms


Penumbra Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Penumbra's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Cyclically Adjusted Revenue per Share Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 19.27 22.04

Penumbra Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.14 20.99 21.36 22.04 23.17

PEN vs GMED, PODD, BRKR: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Penumbra's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Penumbra's Cyclically Adjusted PS Ratio falls into.


PEN
89GF Score
Penumbra Inc PEN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Penumbra's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=9.477/330.2130*330.2130
=9.477

Current CPI (Mar. 2026) = 330.2130.

Penumbra Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.955 241.018 2.678
201609 1.990 241.428 2.722
201612 2.162 241.432 2.957
201703 2.316 243.801 3.137
201706 2.426 244.955 3.270
201709 2.353 246.819 3.148
201712 2.235 246.524 2.994
201803 2.859 249.554 3.783
201806 3.036 251.989 3.978
201809 3.265 252.439 4.271
201812 2.864 251.233 3.764
201903 3.547 254.202 4.608
201906 3.706 256.143 4.778
201909 3.846 256.759 4.946
201912 3.998 256.974 5.137
202003 3.777 258.115 4.832
202006 2.969 257.797 3.803
202009 4.172 260.280 5.293
202012 4.590 260.474 5.819
202103 4.508 264.877 5.620
202106 4.903 271.696 5.959
202109 5.055 274.310 6.085
202112 5.265 278.802 6.236
202203 5.267 287.504 6.049
202206 5.516 296.311 6.147
202209 5.635 296.808 6.269
202212 5.817 296.797 6.472
202303 6.178 301.836 6.759
202306 6.671 305.109 7.220
202309 6.908 307.789 7.411
202312 7.241 306.746 7.795
202403 7.075 312.332 7.480
202406 7.718 314.175 8.112
202409 7.684 315.301 8.047
202412 7.705 315.605 8.062
202503 8.277 319.799 8.547
202506 8.649 322.561 8.854
202509 9.025 324.800 9.175
202512 9.778 324.054 9.964
202603 9.477 330.213 9.477

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $23.17 mean?
Penumbra (PEN) has a Cyclically Adjusted Revenue per Share of $23.17 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Penumbra and its competitors.
Is Penumbra's Cyclically Adjusted Revenue per Share too high?
Penumbra's current Cyclically Adjusted Revenue per Share is $23.17. Overall, Penumbra has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Cyclically Adjusted Revenue per Share compare to GMED and PODD?
Penumbra's Cyclically Adjusted Revenue per Share of $23.17 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Penumbra and its competitors. Penumbra's current Cyclically Adjusted Revenue per Share is $23.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.07, compared to a current price of $318.49 — trading 4.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $23.17. Penumbra's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Penumbra (PEN), the current Cyclically Adjusted Revenue per Share is $23.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (PEN) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of $318.49 is trading 4.1% below its estimated GF Value™ of $332.07. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for PEN:

  • Cyclically Adjusted Revenue per Share: $23.17
  • GF Value™: $332.07 vs. price of $318.49 (4.1% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Penumbra Business Description

Other Exchanges 0P8:Germany
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score

Get the complete analysis for PEN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$318.49
Price
$332.07
GF Value